Welcome to the 2017 Taiwan Society for Therapeutic Radiology and Oncology Conference: “Bring Insight into Impacts” and Both Sides across the Strait Forum
The establishment of Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) brings a lot benefits to cancer field treatment, causing more discussions to hold. Moreover, scholars have more opportunities cooperate one another through this society.
Annals of Nasopharynx Cancer—message from the Editor-in-Chief
It is with immense pleasure that we launch the inaugural issue of Annals of Nasopharynx Cancer—a journal dedicated to the sharing of clinical and translational scientific research in nasopharynx cancer.Nasopharynx cancer is unique; and particularly relevant to the clinical and scientific community in this part of the world. Age-standardised rates of this disease in Southern and Eastern parts of Asia exceed 15 per 100,000 person years, which are at least 15-fold greater than populations from the rest of the world. The endemic form is also invariably associated with Epstein-barr virus (EBV), although the molecular processes driving subsequent tumorigenesis remain elusive. Over the years, such observations have driven the bases for several population genetics and risk-exposure studies.
Editor-in-Chief: Melvin Lee Kiang Chua, MBBS, FRCR, PhD
Melvin L.K. Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and an Instructor with the Duke-NUS Graduate Medical School. His research is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharynx and prostate cancers.Dr. Chua graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-graduate fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Centre, Toronto. Of specific mention, Dr. Chua was part of the multi-member Canadian Prostate Cancer Gene Network (CPC-GENE); the lead site of the International Cancer Genomics Consortium (ICGC) for prostate cancer. The group has published in several high impact journals, including Lancet Oncology, Nature, Nature Genetics, and Nature Communications.